These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38629755)

  • 1. Marketing of Unproven and Unapproved Regenerative Medicine Therapies.
    Rodeo SA
    Sports Health; 2024; 16(3):312-314. PubMed ID: 38629755
    [No Abstract]   [Full Text] [Related]  

  • 2. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products.
    Ikonomou L; Cuende N; Forte M; Grilley BJ; Levine AD; Munsie M; Rasko JEJ; Turner L; Bidkhori HR; Ciccocioppo R; Grignon F; Srivastava A; Weiss DJ; Zettler P; Levine BL;
    Cytotherapy; 2023 Sep; 25(9):920-929. PubMed ID: 37517865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions.
    Weiss DJ; Turner L; Levine AD; Ikonomou L
    Cytotherapy; 2018 Feb; 20(2):165-168. PubMed ID: 29239793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Online marketing practices of regenerative medicine clinics in US-Mexico border region: a web surveillance study.
    Chavez J; Shah NA; Ruoss S; Cuomo RE; Ward SR; Mackey TK
    Stem Cell Res Ther; 2021 Mar; 12(1):189. PubMed ID: 33736697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and emerging global themes in the bioethics of regenerative medicine: the tangled web of stem cell translation.
    Chan S
    Regen Med; 2017 Oct; 12(7):839-851. PubMed ID: 29119870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regenerative medicine: looking backward 10 years further on.
    Kemp P
    Regen Med; 2016 Dec; 11(8):787-800. PubMed ID: 27885902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unproven Regenerative Medicine "Therapies" in Spine.
    Demetriades AK; Orpen NM
    Pain Pract; 2021 Jun; 21(5):607. PubMed ID: 33373102
    [No Abstract]   [Full Text] [Related]  

  • 8. Promoting the ethical use of safe and effective cell-based products: the Andalusian plan on regenerative medicine.
    Cuende N; Álvarez-Márquez AJ; Díaz-Aunión C; Castro P; Huet J; Pérez-Villares JM
    Cytotherapy; 2020 Dec; 22(12):712-717. PubMed ID: 32878735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of clinician adoption of regenerative therapies in the UK and Canada: an ophthalmology perspective.
    Rose JB; May M; Williams DJ
    Regen Med; 2015 May; 10(4):481-93. PubMed ID: 25815640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites' marketing of stem cell therapies.
    Murdoch B; Zarzeczny A; Caulfield T
    BMJ Open; 2018 Feb; 8(2):e019414. PubMed ID: 29490963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying the Risks of Unproven Regenerative Medicine Therapies.
    Marks PW; Hahn S
    JAMA; 2020 Jul; 324(3):241-242. PubMed ID: 32629463
    [No Abstract]   [Full Text] [Related]  

  • 12. Tissue engineering/regenerative medicine ventures should invest early in market research to understand the future market's needs.
    Gemmiti C
    Tissue Eng Part B Rev; 2013 Apr; 19(2):97-8. PubMed ID: 23327734
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory Frameworks for Gene and Cell Therapies in Japan.
    Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
    Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union.
    Jokura Y; Yano K; Yamato M
    J Tissue Eng Regen Med; 2018 Feb; 12(2):e1056-e1062. PubMed ID: 28211195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regenerative Medicine Venturing at the University-Industry Boundary: Implications for Institutions, Entrepreneurs, and Industry.
    Bock AJ; Johnson D
    Adv Exp Med Biol; 2018; 1098():213-236. PubMed ID: 30238374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regenerative medicine: challenges and opportunities.
    Cossu G; Fears R; Griffin G; Ter Meulen V
    Lancet; 2020 Jun; 395(10239):1746-1747. PubMed ID: 32505242
    [No Abstract]   [Full Text] [Related]  

  • 17. Innovative regenerative medicines in the EU: a better future in evidence?
    Corbett MS; Webster A; Hawkins R; Woolacott N
    BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The regulation of veterinary regenerative medicine and the potential impact of such regulation on clinicians and firms commercializing these treatments.
    Nobert KM
    Vet Clin North Am Equine Pract; 2011 Aug; 27(2):383-91. PubMed ID: 21872766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marketing Experimental Stem Cell Therapies in the UK: Biomedical Lifestyle Products and the Promise of Regenerative Medicine in the Digital Era.
    Erikainen S; Couturier A; Chan S
    Sci Cult (Lond); 2020; 29(2):219-244. PubMed ID: 33716572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the FDA regenerative medicine framework: opportunities for stakeholders.
    Richardson E; Akkas F; Master Z
    Regen Med; 2020 Jul; 15(7):1825-1832. PubMed ID: 32815780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.